Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584643 | 1.00 | FFAR4 (0.34) | FFAR4HCRTR2TRPC6FFAR1TBK1 | |
| SCHEMBL29243425 | 0.92 | FFAR4 (0.36) | FFAR4HCRTR2FFAR1TBK1CYP3A4 | |
| SCHEMBL29584172 | 0.92 | FFAR4 (0.36) | FFAR4HCRTR2FFAR1TBK1CYP3A4 | |
| SCHEMBL24424175 | 0.92 | FFAR4 (0.36) | FFAR4HCRTR2FFAR1TBK1CYP3A4 | |
| SCHEMBL24423081 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 | |
| SCHEMBL24423091 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 | |
| SCHEMBL24423068 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 | |
| SCHEMBL24423338 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 | |
| SCHEMBL24423965 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 | |
| SCHEMBL29585204 | 0.88 | MGLL (0.39) | FFAR4HCRTR2FFAR1TBK1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | FFAR4 25/4885HCRTR2 2309/4885TRPC6 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.